Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Barbara Pro, MD, Ranjana H Advani, MD, Pauline Brice, MD, Nancy L Bartlett, MD, Joseph D Rosenblatt, MD, Tim Illidge, PhD, Jeffrey Matous, MD, Radhakrishnan Ramchandren, MD, Michelle A Fanale, MD, Joseph M. Connors, Keenan Fenton, Dirk Huebner, MD, Juan Pinelli, Andrei R. Shustov

Blood (2016) 128 (22): 4144.

https://doi.org/10.1182/blood.V128.22.4144.4144

Published: 2016

Journal Articles

Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-Cell Lymphomas

Michelle A Fanale, MD, Steven M Horwitz, MD, Andres Forero-Torres, MD, Nancy L Bartlett, MD, Ranjana H Advani, MD, Barbara Pro, MD, Robert W Chen, MD, Andrew J Davies, FRCP PhD, Tim Illidge, PhD, Mayur Uttarwar, Dirk Huebner, MD, Hong Ren, MD, Andrei R Shustov, MD

Blood (2016) 128 (22): 2993.

https://doi.org/10.1182/blood.V128.22.2993.2993

Published: 2016

Journal Articles

Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas

Michelle A. Fanale, MD, Steven M. Horwitz, MD, Andres Forero-Torres, MD, Nancy L. Bartlett, MD, Ranjana H. Advani, MD, Barbara Pro, MD, Robert Chen, MD, Andrew Davies, BM PhD, Tim Illidge, PhD, Dirk Huebner, MD, Dana A. Kennedy, PharmD, Andrei R. Shustov, MD

Blood (2013) 122 (21): 4386.

https://doi.org/10.1182/blood.V122.21.4386.4386

Published: 2013

Journal Articles

Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma

Barbara Pro, MD, Ranjana H. Advani, MD, Pauline Brice, MD, Nancy L. Bartlett, MD, Joseph D. Rosenblatt, MD, Tim Illidge, PhD, Jeffrey Matous, MD, Radhakrishnan Ramchandren, MD, Michelle A. Fanale, MD, Joseph M. Connors, MD, Yin Yang, MS, Dirk Huebner, MD, Dana A. Kennedy, PharmD, Andrei R. Shustov, MD

Blood (2013) 122 (21): 1809.

https://doi.org/10.1182/blood.V122.21.1809.1809

Published: 2013

Journal Articles

Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.

Barbara Pro, MD, Ranjana H. Advani, MD, Pauline Brice, MD, Nancy L. Bartlett, MD, Joseph D. Rosenblatt, MD, Tim Illidge, PhD, Jeffrey V. Matous, MD, Radhakrishnan Ramchandren, MD, Michelle A. Fanale, MD, Joseph M. Connors, MD, Yin Yang, MS, Dana A. Kennedy, PharmD, Andrei R. Shustov, MD

Blood (2012) 120 (21): 2745.

https://doi.org/10.1182/blood.V120.21.2745.2745

Published: 2012

Journal Articles

Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant

Blood (2012) 120 (21): 3701.

https://doi.org/10.1182/blood.V120.21.3701.3701

Published: 2012

Journal Articles

Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas

Michelle A. Fanale, MD, Andrei R. Shustov, MD, Andres Forero-Torres, MD, Nancy L. Bartlett, MD, Ranjana H. Advani, MD, Barbara Pro, MD, Robert W. Chen, MD, Andrew Davies, MD, Tim Illidge, PhD, Dana A. Kennedy, PharmD, Steven M. Horwitz, MD

Blood (2012) 120 (21): 60.

https://doi.org/10.1182/blood.V120.21.60.60

Published: 2012

NARROW

Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-Cell Lymphomas

Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas

Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma

Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.

Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant

Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-Cell Lymphomas

Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas

Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma

Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.

Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant

Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only